About Rising Sun Wellness Rx

Our Story

At Rising Sun Wellness Rx, we started with the goal of providing the best products and services to our customers. With over 25 years of experience in the industry, we have established ourselves as a trusted brand that delivers quality every time.

Our Team

Our team is made up of experienced professionals who are dedicated to providing exceptional service. We work closely with our clients to understand their needs and provide tailored solutions that exceed their expectations.

Our Products

We offer a wide range of GPL-1 Based Therapies for Chronic Weight Management and Metabolic Disease.

Rising Sun Wellness Rx: Clinical Overview

What is Rising Sun Wellness Rx?

Clinical Overview of Semaglutide and Tirzepatide

GLP-1–Based Therapies for Chronic Weight Management and Metabolic Disease

Semaglutide and tirzepatide are incretin-based therapies indicated for chronic weight management and glycemic control in appropriate patient populations. These agents target neurohormonal pathways involved in appetite regulation, insulin secretion, and metabolic homeostasis.

This overview is intended for healthcare providers evaluating or managing patients on GLP-1–based pharmacotherapy.

Pharmacologic Classification

Semaglutide: Long-acting GLP-1 receptor agonist
Tirzepatide: Dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist

Both agents are administered once weekly via subcutaneous injection and require dose titration to optimize tolerability.

Mechanism of Action

GLP-1 Receptor Activation

Glucose-dependent stimulation of insulin secretion
Suppression of glucagon secretion
Reduction in hepatic glucose output
Delayed gastric emptying
Central appetite suppression via hypothalamic signaling

Dual GIP/GLP-1 Activity (Tirzepatide)

Augments insulinotropic response
May enhance adipocyte metabolic signaling
Potential additive effects on weight reduction and glycemic control

The glucose-dependent mechanism limits hypoglycemia risk when used as monotherapy.

Indications for Use

Chronic Weight Management

Indicated as adjunctive therapy to reduced-calorie diet and increased physical activity in adults with:

BMI ≥30 kg/m², or
BMI ≥27 kg/m² with at least one weight-related comorbidity

Type 2 Diabetes Mellitus

Glycemic control in adults with type 2 diabetes
Consideration in patients with elevated cardiometabolic risk

Clinical Outcomes

Weight Reduction

Clinical trials demonstrate:

Substantial mean total body weight loss
Significant reductions in visceral adiposity
Dose-dependent response

Weight loss typically progresses over 6–12 months, with maintenance requiring continued therapy.

Glycemic Control

Significant HbA1c reduction
Improvement in fasting and postprandial glucose
Low intrinsic hypoglycemia risk (unless combined with insulin or insulin secretagogues)

Cardiovascular Considerations

Certain GLP-1 receptor agonists have demonstrated:

Reduction in major adverse cardiovascular events in patients with established cardiovascular disease

Renal Considerations

Slowing of diabetic kidney disease progression in select populations
Reduction in albuminuria in clinical trials

Safety Profile

Common Adverse Effects

Primarily gastrointestinal and dose-dependent:

Nausea
Vomiting
Diarrhea
Constipation
Dyspepsia

Symptoms are typically most pronounced during titration.

Warnings and Precautions

Pancreatitis

Discontinue if suspected
Evaluate persistent severe abdominal pain

Gallbladder Disease

Increased incidence of cholelithiasis and cholecystitis

Hypoglycemia

Increased risk when combined with insulin or sulfonylureas
Consider dose adjustment of concomitant agents

Acute Kidney Injury

Secondary to dehydration from GI losses

Delayed Gastric Emptying

May impact absorption of oral medications
Use caution in patients with severe gastroparesis

Thyroid C-Cell Tumor Risk (Class Warning)

Contraindicated in patients with:

Personal or family history of medullary thyroid carcinoma
Multiple endocrine neoplasia syndrome type 2

Patient Selection Considerations

Appropriate candidates typically include patients who:

Have obesity or overweight with metabolic comorbidities
Have demonstrated inadequate response to lifestyle intervention alone
Have type 2 diabetes requiring improved glycemic and/or weight control
Would benefit from cardiometabolic risk reduction

Caution in patients with:

History of pancreatitis
Significant gastrointestinal disease
Severe renal impairment (monitor hydration status closely)

Provider FAQ

How should dose titration be approached?

Gradual dose escalation over several weeks is recommended to mitigate gastrointestinal adverse effects. Delays in titration may be appropriate based on tolerability.

What monitoring is recommended?

Weight and BMI
HbA1c (if diabetic or prediabetic)
Renal function in at-risk patients
Signs/symptoms of pancreatitis or gallbladder disease
Concomitant medication adjustments to prevent hypoglycemia

When should therapy be discontinued?

Suspected pancreatitis
Intolerable persistent gastrointestinal adverse effects
Pregnancy
Development of contraindicating conditions

What should be discussed with patients regarding long-term use?

Patients should be counseled that obesity is a chronic disease. Discontinuation of therapy is commonly associated with weight regain. Long-term pharmacotherapy may be required to maintain outcomes.

Are these agents appropriate for cosmetic weight loss?

No. Semaglutide and tirzepatide are indicated for chronic weight management in patients meeting BMI and comorbidity criteria. Use should align with evidence-based guidelines.

Clinical Summary

Semaglutide and tirzepatide provide targeted incretin-based therapy addressing central appetite regulation, glycemic control, and cardiometabolic risk. Their role extends beyond weight reduction to comprehensive metabolic disease management.

Appropriate patient selection, structured titration, and ongoing monitoring are essential to optimize clinical outcomes and mitigate adverse effects.

Tennessee-licensed 503A Compounding Pharmacy